Literature DB >> 22766361

Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection?

Wen-Tsan Chang1, Wei-Yu Kao, Gar-Yang Chau, Chien-Wei Su, Hao-Jan Lei, Jaw-Ching Wu, Cheng-Yuan Hsia, Wing-Yiu Lui, Kuang-Liang King, Shou-Dong Lee.   

Abstract

BACKGROUND: Indications for resection of non-early-stage hepatocellular carcinoma (HCC) remain controversial. This study aimed to identify factors that affect outcome of patients with Barcelona Clinical Liver Cancer Classification (BCLC) stage B or stage C HCC after hepatic resection.
METHODS: From 1991 to 2006, 478 patients with HCC (BCLC stage B, n = 318 and BCLC stage C, n = 160) who underwent resection were enrolled. Factors in terms of overall survival and recurrence were analyzed.
RESULTS: After a median follow-up of 29.5 months, 304 patients had died. The cumulative overall survival rate at 5 years was 46.5% in BCLC stage B patients and 29.1% in stage C patients (P < .001). Multivariate analysis disclosed that serum albumin levels ≤4 g/dL, indocyanine green retention rate at 15 minutes >10%, serum creatinine >1.2 mg/dL, multinodularity, Edmondson stage III or IV in tumor cell differentiation, and the presence of macroscopic vascular invasion were independent risk factors of poor overall survival. There were 331 patients with tumor recurrence after resection. Recurrence rate was less in BCLC stage B than that in BCLC stage C (P = .001). Multivariate analysis showed that serum albumin level ≤4 g/dL, multinodularity, cut margin ≤1 cm, and Edmondson stage III or IV were associated with the recurrence of HCC.
CONCLUSION: Hepatic resection can provide long-term survival benefit in selected BCLC stage B or C patients with compensated liver function, especially in those presenting with a single neoplasm without vascular invasion.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22766361     DOI: 10.1016/j.surg.2012.03.024

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  43 in total

1.  Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.

Authors:  Yi-Chia Chan; Catherine S Kabiling; Vinod G Pillai; Gustavo Aguilar; Chih-Chi Wang; Chao-Long Chen
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

Review 2.  Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors:  Gar-Yang Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 3.  Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Multiple Tumors Located in the Same Section Are Associated with Better Outcomes After Hepatic Resection for HCC Patients Meeting the Milan Criteria.

Authors:  Tao Lv; Li Jiang; Lunan Yan; Jiayin Yang; Bo Li; Tianfu Wen; Yong Zeng; Wentao Wang; Mingqing Xu
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

5.  Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.

Authors:  Zhenwei Peng; Mengchao Wei; Shuling Chen; Manxia Lin; Chunlin Jiang; Jie Mei; Bin Li; Yu Wang; Jiaping Li; Xiaoyan Xie; Ming Kuang
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

Review 6.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 7.  Liver resection for intermediate hepatocellular carcinoma.

Authors:  Peng-Sheng Yi; Ming Zhang; Ji-Tong Zhao; Ming-Qing Xu
Journal:  World J Hepatol       Date:  2016-05-18

Review 8.  Liver surgery in cirrhosis and portal hypertension.

Authors:  Christina Hackl; Hans J Schlitt; Philipp Renner; Sven A Lang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 9.  Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Authors:  Xavier Adhoute; Guillaume Penaranda; Jean Luc Raoul; Patrice Le Treut; Emilie Bollon; Jean Hardwigsen; Paul Castellani; Hervé Perrier; Marc Bourlière
Journal:  World J Hepatol       Date:  2016-06-18

Review 10.  Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Simone Conci; Alessandro Valdegamberi; Marco Vitali; Francesca Bertuzzo; Michela De Angelis; Guido Mantovani; Calogero Iacono
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.